InvEstigating oeStrogen Signalling and the Effect upoN the exTracelluar Matrix In pAtients With Obstructive Lung Disease (ESSENTIAL)
invEstigating oeStrogen Signalling and the Effect upoN the exTracelluar Matrix In pAtients With Obstructive Lung Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Gill Radcliffe Ms, MRes
- Phone Number: +442071888070
- Email: gillian.radcliffe@gstt.nhs.uk
Study Contact Backup
- Name: Chris Mwasuku
- Email: Christine.Mwasuku@gstt.nhs.uk
Study Locations
-
-
-
London, United Kingdom, SE1 7EH
- Recruiting
- Guys & St Thomas NHS Foundation Trust
-
Contact:
- Gillian Radcliffe, MRES
- Phone Number: +442071888070
- Email: gillian.radcliffe@gstt.nhs.uk
-
Contact:
- Christine Mwasuku, MSc
- Phone Number: +442071888070
- Email: christine.mwasuku@kcl.ac.uk
-
Principal Investigator:
- Mona Bafadhel, PhD
-
Sub-Investigator:
- Christine Mwasuku, MSc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Men and women aged > 18 years.
- For female participants: pre-menopausal, peri-menopausal and post-menopausal women can all be included.
- Participants willing and able to give informed consent for participation in the study.
- Healthy controls <10 pack year history (participants without Asthma or COPD).
Exclusion Criteria:
- Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus.
- Alcohol or recreational drug abuse, is defined as when the use is harmful as per NHS definition.
- History of psychiatric, medical, or surgical disorders.
- Pregnant
- Unable to provide written informed consent
- History of advanced medical conditions with an expected prognosis of < 3 years.
- Patients with a history of active cancer.
- Patients on long term oxygen (ambulatory oxygen).
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
People with physician-diagnosed disease (Asthma and/or COPD).
|
No Intervention
|
|
Healthy controls
People with no physician-diagnosed disease (Asthma and/or COPD).
|
No Intervention
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lung Function (FEV1 change from baseline)
Time Frame: Through study completion, minimum of 1 year
|
Lung function measures the volume of air exhaled at specific time points during complete exhalation by force, which is preceded by a maximal inhalation.
|
Through study completion, minimum of 1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oscillometry
Time Frame: Through study completion, minimum of 1 year
|
Oscillometry is a technique that measures the mechanical impedance of the respiratory system, or how well the lungs are functioning.
|
Through study completion, minimum of 1 year
|
|
The COPD Assessment Test (CAT)
Time Frame: Through study completion, minimum of 1 year
|
The COPD Assessment Test (CAT) is a questionnaire for people with Chronic Obstructive Pulmonary Disease (COPD).
It is designed to measure the impact of COPD on a person's life, and how this changes over time
|
Through study completion, minimum of 1 year
|
|
Asthma Control Questionnaire (ACQ)
Time Frame: Through study completion, minimum of 1 year
|
A simple questionnaire to measure the adequacy of asthma control and change in asthma control which occurs either spontaneously or as a result of treatment.
|
Through study completion, minimum of 1 year
|
|
Asthma Quality of Life Questionnaire (AQLQ)
Time Frame: Through study completion, minimum of 1 year
|
A disease-specific health-related quality of life instrument that taps both physical and emotional impact of disease.
The instrument should not be confused with the measure developed by Marks GB and colleagues, which carries the same name.
|
Through study completion, minimum of 1 year
|
|
EQ-5D-5L
Time Frame: Through study completion, minimum of 1 year
|
The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).
|
Through study completion, minimum of 1 year
|
|
The Greene Climacteric Scale (GCS)
Time Frame: Through study completion, minimum of 1 year
|
is a questionnaire that helps to determine the severity of menopausal symptoms.
|
Through study completion, minimum of 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Mona Bafadhel, King's College London
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 326236
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.